The earnings call highlighted Bioventus's strong financial performance, strategic growth in key segments, and effective cash flow and debt management. Despite challenges from divestitures, tariffs, and foreign exchange impacts, the company maintained its guidance and demonstrated resilience and adaptability.

Company Guidance -

Q3 2025

In the Bioventus Inc. Second Quarter 2025 Earnings Conference Call, the company reiterated its full-year financial guidance, highlighting several key metrics. For the second quarter, Bioventus reported revenue of $148 million, reflecting a 6% organic growth despite a challenging comparison in pain treatments. The company achieved adjusted earnings of $0.21 per share, marking a 31% increase compared to the previous year, and an adjusted EBITDA margin of 23%. They expect to generate 100 basis points of adjusted EBITDA margin expansion for the year, even after absorbing $5 million in headwinds from tariffs and foreign exchange impacts. Bioventus plans a limited commercial release of its new PNS products, StimTrial and TalisMann, in select U.S. markets starting in the third quarter, with broader rollout anticipated in early 2026. The company aims to nearly double its cash flow from operations compared to 2024, with expectations to reduce net leverage to below 2.5x by the end of 2025.

Strong Revenue Growth and Profitability

Bioventus reported second quarter revenue of $148 million, achieving above-market organic growth of 6%. Adjusted earnings per share increased by 31% to $0.21, with an adjusted EBITDA margin of 23%.

Surgical Solutions and Restorative Therapies Growth

The Surgical Solutions segment delivered strong double-digit growth in ultrasonics, while the Restorative Therapies business, led by Exogen, accelerated to double-digit growth, validating the company's strategic focus and investments.

510(k) Clearance for Pain Treatment Innovations

Bioventus received 510(k) clearance for StimTrial and TalisMann, expanding into the peripheral nerve stimulation market for chronic pain management. This market is expected to grow over 20% annually in the U.S., with a total addressable market of approximately $2 billion.

Improved Cash Flow and Debt Management

The company generated $26 million in cash flow from operations, representing an increase of $11 million from the prior year. It also refinanced its credit facility, lowering the interest rate by 75 basis points and reducing annual debt repayment obligations.

Reaffirmed Financial Guidance

Bioventus reaffirmed its 2025 financial guidance, including 6%-8% organic revenue growth, adjusted EBITDA of $112 million to $116 million, and EPS of $0.64 to $0.68.

Bioventus (BVS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BVS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.11 / -	0.06	―	―	―
Aug 06, 2025	2025 (Q2)	0.16 / 0.21	0.19	10.53% (+0.02)
May 06, 2025	2025 (Q1)	0.03 / 0.08	0.07	14.29% (<+0.01)
Mar 11, 2025	2024 (Q4)	0.08 / 0.15	0.07	114.29% (+0.08)
Nov 05, 2024	2024 (Q3)	0.02 / 0.06	0.05	20.00% (<+0.01)
Aug 06, 2024	2024 (Q2)	0.07 / 0.19	0.14	35.71% (+0.05)
May 07, 2024	2024 (Q1)	-0.07 / 0.07	-0.26	126.92% (+0.33)
Mar 12, 2024	2023 (Q4)	0.02 / 0.07	-0.06	216.67% (+0.13)
Nov 07, 2023	2023 (Q3)	-0.02 / 0.05	0.08	-37.50% (-0.03)
Aug 08, 2023	2023 (Q2)	>-0.01 / 0.14	0.1	40.00% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BVS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$6.14	$7.29	+18.73%
May 06, 2025	$7.03	$6.20	-11.81%
Mar 11, 2025	$8.76	$10.80	+23.29%
Nov 05, 2024	$13.71	$11.48	-16.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bioventus (BVS) report earnings?

Bioventus (BVS) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Bioventus (BVS) earnings time?

Bioventus (BVS) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BVS EPS forecast?

BVS EPS forecast for the fiscal quarter 2025 (Q3) is 0.11.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing